Nanomaterials pose significant challenges in tracing post-administration within living organisms. In this regard, nuclear imaging emerges as an invaluable translational tool, enabling the precise and time-resolved quantification of nanomaterial presence with exceptional sensitivity at the whole-body level.

Llop's group leverages multi-radionuclide labelling strategies to assess the biodistribution, biological fate, and stability of protein corona formation across various nanomaterial types. Furthermore, they harness positron or gamma emitters to evaluate the tumor accumulation capacity of therapeutic nanoparticles. These nanoparticles are meticulously designed to deliver conventional drugs, therapeutic radionuclides for radiotherapy, or boron-rich nanoparticles for boron neutron capture therapy (BNCT) directly to the target site.